Drugs / SC01009
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06693362 | Jan 2025 → Jun 2026 overdue | viral pneumonia | Ruijin Hospital | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07131150 | Aug 2025 → Jul 2028 expected | idiopathic pulmonary fibrosis | Ruijin Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SC01009 | “SC01009 injection is a cellular therapy product developed by Zhejiang Shengchuang Precision Medical Technology Co., Ltd.” NCT06693362 ↗ |
| Modality | Cell therapy | “SC01009 injection is a cellular therapy product” NCT06693362 ↗ |
| Route | Intravenous | “SC01009) is administered via intravenous infusion” NCT06693362 ↗ |